

PTD-mediated delivery of anti-cell death proteins/peptides and therapeutic enzymes[☆]

Sadamitsu Asoh^{*}, Shigeo Ohta

Department of Biochemistry and Cell Biology, Institute of Development and Aging Sciences, Graduate School of Medicine, Nippon Medical School, 1-396, Kosugi-cho, Nakahara-ku, Kawasaki-city, Kanagawa 211-8533, Japan

Received 14 August 2007; accepted 12 September 2007

Available online 13 November 2007

Abstract

Millions of unnecessary cells are removed from our body everyday by apoptosis to ensure our survivals. Apoptosis is a highly coordinated process. Failure in apoptotic regulation results in disease. A large number of studies have demonstrated that accelerated apoptosis is involved in degenerative diseases, ischemic injuries, immunodeficiency and infertility. These studies have also revealed the molecular mechanisms of apoptosis signal transduction to provide therapeutic targets. On the other hand, protein transduction technology has been developed to deliver full-length proteins to various tissues including the brain. So far, many studies have shown that *in vivo* delivery of therapeutic proteins/peptides, including anti-apoptotic proteins, an anti-oxidant enzyme, a neuroprotectant, enzymes involved in purine or tyrosine metabolism, caspase inhibitors, c-Jun N-terminal kinase inhibitors and an NF- κ B inhibitor, by protein transduction technology mitigates various diseases in animal models.

© 2007 Elsevier B.V. All rights reserved.

Keywords: Apoptosis; Bcl-2 family; Enzyme replacement; Ischemia/reperfusion injury; Necrosis; Neurodegenerative diseases; Peptide inhibitors; Protein therapy

Contents

1. Introduction	500
2. Regulation of apoptosis; molecular mechanisms and components	501
2.1. Apoptosis signaling pathways	501
2.2. Mitochondria	501
2.2.1. Mitochondrial apoptogenic factors	501
2.2.2. Ca^{2+} and mitochondrial permeability transition	501
2.3. Bcl-2 family	502
2.3.1. Heterodimerization of anti-apoptotic and pro-apoptotic family members.	502
2.3.2. Bcl-2 and Bcl-x _L	502
2.3.3. Three-dimensional structure of Bcl-x _L and ion channel activity	502
3. Protein transduction.	502
4. Delivery of anti-cell death proteins and therapeutic enzymes	503

[☆] This review is part of the *Advanced Drug Delivery Reviews* theme issue on “Membrane Permeable Peptide Vectors: Chemistry and Functional Design for the Therapeutic Applications”.

^{*} Corresponding author. Tel.: +81 44 733 1859; fax: +81 44 733-9268.

E-mail address: sada@nms.ac.jp (S. Asoh).

4.1.	Anti-apoptotic Bcl-x _L protein	503
4.1.1.	Ischemia/reperfusion injury of the brain	503
4.1.2.	Retrograde neurodegeneration.	506
4.1.3.	Islets for transplantation.	506
4.2.	FNK, genetically engineered Bcl-x _L with a gain-of-function phenotype	506
4.2.1.	Construction of super anti-apoptotic protein FNK	506
4.2.2.	Ischemia/reperfusion injuries of the brain, liver and heart	506
4.2.3.	Liver necrosis induced by carbon tetrachloride	506
4.2.4.	Delivery to the inner ear and the cartilage	507
4.2.5.	Bone marrow transplantation	507
4.2.6.	Cryopreservation	507
4.3.	Caspase inhibitor, X-linked inhibitor of apoptosis protein (XIAP).	508
4.3.1.	The structure of XIAP	508
4.3.2.	Brain ischemia	508
4.4.	Glial cell-line-derived neurotrophic factor (GDNF)	508
4.4.1.	GDNF as a neuroprotectant	508
4.4.2.	Brain ischemia	508
4.4.3.	Parkinson's disease model	508
4.5.	Tyrosine hydroxylase (TH) and Parkinson's disease model	508
4.6.	Cu/Zn-superoxide dismutase (SOD); a native or denatured form for transduction	509
4.6.1.	Anti-oxidant enzyme, SOD	509
4.6.2.	TAT-SOD; a denatured form with lower activity for delivery to the pancreas and brain	509
4.6.3.	PEP-1-SOD; a native form with higher activity for delivery to the brain.	509
4.7.	Purine nucleoside phosphorylase (PNP): delivery and sheltering from neutralization	509
5.	Delivery of anti-cell death peptides	510
5.1.	BH4 domain of Bcl-2 and Bcl-x _L	510
5.1.1.	X-ray and heart ischemic injury.	510
5.1.2.	Comparison between TAT-BH4 and TAT-Bcl-x _L	510
5.2.	Caspase inhibitor peptide BIR3/RING derived from XIAP; brain ischemia and seizures induced by kainate	510
5.3.	Peptide inhibitors of c-Jun N-terminal kinase (JNK).	511
5.3.1.	JNK signal signaling pathway as a therapeutic target.	511
5.3.2.	D- and L-forms of JNK inhibitor; brain and heart injuries	511
5.3.3.	Otoprotection by topical application to the inner ear	511
5.3.4.	Smaller JNK inhibitor; cerebral ventricular injection for brain ischemia	511
5.4.	Glutamate receptor sub-unit 6 (GluR6) C-terminus derived peptide	512
5.4.1.	GluR6 as a therapeutic target for seizures.	512
5.4.2.	Cerebral ventricular injection for ischemia- and kainate-induced brain injuries.	512
5.5.	Peptide inhibitor of NF-κB: IκB kinase inhibitor NEMO-binding domain peptide	512
5.5.1.	NF-κB as a therapeutic target.	512
5.5.2.	Islets for transplantation.	512
6.	Conclusions	512
	References	513

1. Introduction

Apoptosis is a biological process of immense importance and is physiologically essential for normal development and tissue homeostasis in adults to regulate the balance between proliferation and cell death; therefore, dysregulation of apoptosis can lead to disease. Apoptosis is known or suspected to contribute to acute diseases, such as stroke, heart attack and liver failure, through inducing massive cell death in tissues or organs, and to certain slow-progressing diseases, such as Parkinson's disease. As apoptosis machinery is equipped in almost all cells of our body, it is an attractive target of therapeutic intervention. It is known that a wide range of stimuli, regardless of intra-cellular or extra-cellular stimuli, can induce apoptosis, which is regulated in different ways from cell to cell, and is carried out in a stimulus-

and cell type-dependent manner. The common components of the apoptosis mechanism are finally activated in the execution of apoptosis.

For successful systemic drug delivery, it is important to pass through difficult barriers, such as the cellular membrane or specialized cellular barriers, for example, the blood–brain barrier. After several observations that HIV-1 Tat protein [1,2] and homeodomain protein Antennapedia [3,4] can enter cells, many peptide sequences, the protein transduction domain (PTD) or cell-penetrating peptide (CPP), have been identified to be responsible for membrane translocation. The finding that systemically administered TAT-fused β-galactosidase is delivered into the brain [5] has encouraged studies in delivering therapeutic proteins/peptides. This article is intended to review studies on systemic delivery of anti-cell death proteins/peptides intervening in apoptosis

Download English Version:

<https://daneshyari.com/en/article/2071813>

Download Persian Version:

<https://daneshyari.com/article/2071813>

[Daneshyari.com](https://daneshyari.com)